Wake Forest University Health Sciences

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, Wake Forest University Health Sciences sits in the top decile of US sponsors by registered trial count (#27 of 15,742 sponsors by registered trial count).

1,140 total trials 174 currently recruiting 724 completed early-phase tilt top decile by trial count

Wake Forest University Health Sciences: 1,140 sponsored US clinical trials, 174 recruiting.

Wake Forest University Health Sciences sponsors 1,140 registered US clinical trials on ClinicalTrials.gov, 174 of them currently recruiting, and 724 completed. 111 of these trials are in Phase 3-4 (later-stage) and 239 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Breast Cancer, with 9 trials.

Top-decile sponsor footprint

Wake Forest University Health Sciences ranks in the top decile of sponsors by registered trial count (#27 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

F 44/100

724 of 885 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (81.8%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

1,140 total, page 17 of 23

COMPLETED NA

Efficacy of Nitric Oxide Administration in Attenuating Ischemia/Reperfusion Injury During Neonatal Cardiopulmonary Bypass

NCT02151877

COMPLETED

Systolic Blood Pressure Measurement in Critically-ill Patients

NCT02366507

COMPLETED NA

Breast Health Education for Underserved Latino Women

NCT02205736

COMPLETED Phase 4

Pain Expectations in Subjects With Osteoarthritis

NCT02155257

TERMINATED NA

Cryosurgery and Radiation Therapy in Treating Patients With Painful Bone Metastases

NCT01767935

TERMINATED NA

Low-Dose Total Lymphoid Irradiation in Treating Patients With Refractory Chronic Graft-versus-Host Disease After Donor Stem Cell Transplant

NCT02109809

TERMINATED NA

Angiotensin Receptors and Age Related Mitochondrial Decline in HIV Patients

NCT02606279

COMPLETED NA

Botanical Oils Study to Determine Genetic Differences in the Way Your Body Processes Fats in Edible Oils

NCT02337231

TERMINATED

ROP Screening: Comparison of Pain Using Two Eyelid Retractors

NCT02152046

TERMINATED Phase 2

Efficacy of Intrathecal Oxytocin in Patients With Neuropathic Pain

NCT02100956

COMPLETED Phase 2

A Study of Regorafenib in Advanced Pancreatic Cancer Patients

NCT02080260

COMPLETED NA

Continuous Infusion Versus Bolus Dosing for Pain Control After Pediatric Cardiothoracic Surgery

NCT02112448

COMPLETED NA

Effectiveness of an mHealth Colorectal Cancer Screening Intervention

NCT02088333

TERMINATED

LCI-GU-BLA-SPEC-001: Aurora Kinase Expression in Muscle-Invasive Bladder Cancer

NCT02164942

COMPLETED

Hemodynamic Monitoring in Hepatopancreaticobiliary (HPB) Surgery

NCT03612687

TERMINATED NA

Interactive Gentle Yoga in Improving Quality of Life in Patients With Stage I-III Breast Cancer Undergoing Radiation Therapy

NCT02023008

COMPLETED NA

Multivitamin Adherence Following Bariatric Surgery

NCT02124889

COMPLETED

Stress and Coping in Caregivers of Younger Patients With Cancer

NCT02725385

COMPLETED

Plasma Cytochrome c as Biomarker of Traumatic Injury and Predictor of Outcome

NCT02440373

COMPLETED NA

Effects of a Cocoa Shot on the Human Brain 2

NCT02080845

COMPLETED

Comparative Effectiveness of Emergency Ultrasound Guided Management of Pediatric Soft Tissue Infections

NCT02099227

COMPLETED

Exhaled NO as a Biomarker of Gestational OSA and Persistence Postpartum

NCT02100943

COMPLETED Phase 2

Preventing Anthracycline Cardiovascular Toxicity With Statins (PREVENT)

NCT01988571

COMPLETED NA

Bovine Lactoferrin Supplement in Improving Taste in Patients With Cancer Receiving Chemotherapy

NCT01941810

COMPLETED NA

Impact of Weight Loss on Physical Function

NCT02079051

TERMINATED NA

Bioelectrical Impedance Phase Angle in Predicting Treatment Outcome in Patients With Extensive Stage Small Cell Lung Cancer Receiving First-Line Chemotherapy

NCT02011087

TERMINATED Phase 2

Efficacy of Spinal Oxytocin in Healthy Volunteers

NCT01996605

COMPLETED NA

Tolerability and Satisfaction With Evie

NCT01969812

COMPLETED NA

Latinos Combating Diabetes

NCT01831921

COMPLETED NA

Vitamin D Supplementation and Muscle Function in Older Adults

NCT02015611

COMPLETED NA

Health Education Intervention in Reducing Weight Gain in Patients With Newly Diagnosed Stage I-IV Breast Cancer Undergoing Chemotherapy

NCT01941784

COMPLETED NA

CyberKnife® as Monotherapy or Boost SBRT for Intermediate or High Risk Localized Prostate Cancer

NCT01985828

COMPLETED Phase 2

Omega-3 Fatty Acid in Treating Patients With Stage I-III Breast Cancer

NCT01869764

COMPLETED

HEART Pathway Implementation

NCT02056964

COMPLETED

LCI-HEM-SPEC-001: Tissue Collection for Genetic Analysis of Acute Myelogenous Leukemia

NCT01999556

COMPLETED Phase 1

High-Dose Trivalent Influenza Vaccine in Inducing Immune Response Patients With Central Nervous System Tumors

NCT01941758

COMPLETED Phase 1

CPI-613 in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer

NCT01931787

COMPLETED NA

High-resolution, Relational, Resonance-based, Electroencephalic Mirroring (HIRREM) to Relieve Insomnia

NCT01971567

TERMINATED Phase 2

Bupivacaine for Benign Headache in the ED

NCT01785459

TERMINATED Phase 4

Acetaminophen Use in Labor - Does Use of Acetaminophen Reduce Neuraxial Analgesic Drug Requirement During Labor?

NCT02181387

COMPLETED NA

Effects of a Cocoa Shot on the Human Brain

NCT01924481

COMPLETED NA

Cardiac Magnetic Resonance Imaging Strategy for the Management of Patients With Acute Chest Pain and Detectable to Elevated Troponin

NCT01931852

COMPLETED Phase 1

Sildenafil Citrate Before Surgery in Improving Kidney Function in Patients With Kidney Cancer

NCT01950923

COMPLETED Phase 2

Combined Spinal-Epidural Temperature and Duration of Action

NCT02020304

COMPLETED NA

Comparing Types of Implementation of a Shared Decision Making Intervention

NCT02047929

TERMINATED

ClinicCompanion. Compared to the Use of a Goniometer

NCT02043639

TERMINATED Phase 2

CPI-613 in Treating Patients With Myelodysplastic Syndromes Who Failed Previous Therapy

NCT01902381

COMPLETED NA

Bioelectrical Impedance Measurement for Predicting Treatment Outcome in Patients With Newly Diagnosed Acute Leukemia

NCT01869777

COMPLETED Phase 1

CPI-613 in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer

NCT01839981

COMPLETED

Evaluation of Efficacy and Accuracy of Aquamantys Device in General Surgery

NCT01929902

← Previous Page 17 of 23 Next →

Phase Distribution

PhaseTrial count
Phase 1 96
Phase 2 143
Phase 3 31
Phase 4 80

What is open in the Wake Forest University Health Sciences pipeline

174 recruiting of 1,140 indexed (15% open); 724 completed (64%).

Phase mix: 111 late (III/IV) vs 239 early (I/II) (early-phase heavy).

Top condition: Breast Cancer (9 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Wake Forest University Health Sciences: open-pipeline peers nationwide

Peers matched on 1,140 registered trials and 15% open enrollment, not the therapeutic-area sidebar.

Wake Forest University Health Sciences sits at or above the median trial volume and below the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 05001,0001,500 8%10%12%14%16%18%20% Total trials Recruiting share Wake Forest University Health SciencesUniversity of Alabama at BirminghamNYU Langone HealthUniversity of North Carolina, Chapel HillUniversity of FloridaBaylor UniversityCornell UniversityArrowhead Regional Medical CenterAurinia Pharmaceuticals
Wake Forest University Health Sciences sits at or above the median trial volume and below the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Wake Forest University Health Sciences sits at or above the median trial volume and below the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 1,140 trials (± recruiting share)

Sponsors near 15% open enrollment (± trial volume)

What to do with this Wake Forest University Health Sciences page

1,140 registered trials is a research-attention snapshot, not an endorsement of Wake Forest University Health Sciences or any single study.

  • 174 of Wake Forest University Health Sciences's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Breast Cancer is the condition Wake Forest University Health Sciences studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Breast Cancer trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Wake Forest University Health Sciences pipeline card: 1,140 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.